/JBIO
JBIO Stock - Jade Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$17.03+2.84%
+$0.47 (+2.84%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+64.4%upside
Target: $28.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.86 – $17.20
TARGET (TP)$28.00
STOP LOSS$15.67
RISK/REWARD1:8.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.04
52W High$100.10
52W Low$6.57
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-282,000 | $-96,000 | $-68,000 | $-15,000 | $-1,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-74,596,000 | $-81,409,000 | $-53,237,000 | $-23,022,000 | $-8,889,000 |
| Net Income | $-69,628,000 | $-75,521,000 | $-51,511,000 | $-22,963,000 | $-9,611,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-85.26 | $-100.38 | $-73.67 | $-32.96 | $-14.00 |
Company Overview
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 1.8% Upside
Now
$10
Low
$17
Average
$28
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 9th 2025 | BTIG Research | Initiation | Buy | $28 |
| July 14th 2025 | Jefferies | Initiation | Buy | $16 |
| June 16th 2025 | Guggenheim | Upgrade | Buy | $14 |
| May 7th 2025 | Wedbush | Initiation | Outperform | $17 |
| May 5th 2025 | Stifel | Initiation | Buy | $19 |
| May 2nd 2025 | TD Cowen | Initiation | Buy | $10 |
Earnings History & Surprises
JBIOBeat Rate
50%
Last 4 quarters
Avg Surprise
+3.7%
EPS vs Estimate
Beats / Misses
2/1
1 met exactly
Latest EPS
$-0.48
Q4 2025
EPS Surprise History
Q1 25
0.0%
$-0.19vs$-0.19
Q2 25
+98.9%
$-0.09vs$-8.40
Q3 25
-100.0%
$-0.86vs$-0.43
Q4 25
+15.8%
$-0.48vs$-0.57
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.46 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.57 | $-0.48 | +15.8% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.43 | $-0.86 | -100.0% | ✗ MISS |
Q2 2025 | Apr 25, 2025 | $-8.40 | $-0.09 | +98.9% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.19 | $-0.19 | 0.0% | = MET |
Latest News
Jade Biosciences Raises $45M in Private Stock Offering Of 3.21M Shares At $14/Share To Advance Autoimmune Drug Research
📈 PositiveBenzinga•Dec 15, 2025, 12:08 PM
Clear Street Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $25
📈 PositiveBenzinga•Nov 25, 2025, 12:27 PM
Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $17
📈 PositiveBenzinga•Nov 18, 2025, 02:12 PM
Jade Biosciences Q3 EPS $(0.48) Beats $(0.66) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:33 PM
Reported Saturday, Jade Biosciences Presents Translational Modeling Linking APRIL Suppression To Proteinuria Reduction And Clinical Remission In IgA Nephropathy
📈 PositiveBenzinga•Nov 10, 2025, 09:11 AM
Jade Biosciences To Present New Preclinical Safety, Translational Data For Immunoglobulin A Nephropathy Candidate JADE101 American Society of Nephrology Kidney Week
📈 PositiveBenzinga•Oct 17, 2025, 08:09 PM
Jade Biosciences shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $28 price target.
📈 PositiveBenzinga•Oct 9, 2025, 12:58 PM
BTIG Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $28
📈 PositiveBenzinga•Oct 9, 2025, 10:09 AM
Jade Biosciences announces PIPE financing of $135M in gross proceeds, Cash Runway Into 2028
📈 PositiveBenzinga•Oct 7, 2025, 11:07 AM
Jade Biosciences Unveils JADE201, Investigational Half-Life Extended, Afucosylated Monoclonal Antibody Targeting B-Cell Activating Factor Receptor
📈 PositiveBenzinga•Oct 7, 2025, 11:06 AM
Jade Biosciences Starts Phase 1 Trial Of JADE101 Antibody For IgA Nephropathy, Eyes 2026 Data
📈 PositiveBenzinga•Sep 2, 2025, 11:03 AM
Jade Biosciences Posts Wider Loss in Q2
📉 NegativeThe Motley Fool•Aug 13, 2025, 09:03 PM
Frequently Asked Questions about JBIO
What is JBIO's current stock price?
Jade Biosciences, Inc. (JBIO) is currently trading at $17.03 per share. The stock has moved +2.84% today.
What is the analyst price target for JBIO?
The average analyst price target for JBIO is $28.00, based on 1 analyst.
What sector is Jade Biosciences, Inc. in?
Jade Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is JBIO's market cap?
Jade Biosciences, Inc. has a market capitalization of $0.56 billion, making it a small-cap company.
Does JBIO pay dividends?
No, Jade Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
TECX
Tectonic Therapeutic, Inc.
$19.56
Mkt Cap: $0.4B
XOMA
XOMA Royalty Corp.
$25.39
Mkt Cap: $0.3B
Explore stocks similar to JBIO for comparison